KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Goodwill (2016 - 2025)

Historic Goodwill for Astrazeneca (AZN) over the last 16 years, with Q4 2025 value amounting to $21.2 billion.

  • Astrazeneca's Goodwill rose 103.21% to $21.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $21.2 billion, marking a year-over-year increase of 103.21%. This contributed to the annual value of $21.2 billion for FY2025, which is 103.21% up from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's Goodwill is $21.2 billion, which was up 103.21% from $21.2 billion recorded in Q3 2025.
  • Astrazeneca's Goodwill's 5-year high stood at $21.2 billion during Q4 2025, with a 5-year trough of $11.8 billion in Q1 2021.
  • In the last 5 years, Astrazeneca's Goodwill had a median value of $20.0 billion in 2023 and averaged $19.6 billion.
  • In the last 5 years, Astrazeneca's Goodwill soared by 12354.76% in 2021 and then plummeted by 241.74% in 2022.
  • Astrazeneca's Goodwill (Quarter) stood at $20.3 billion in 2021, then fell by 2.42% to $19.8 billion in 2022, then grew by 1.15% to $20.0 billion in 2023, then grew by 4.87% to $21.0 billion in 2024, then rose by 1.03% to $21.2 billion in 2025.
  • Its Goodwill stands at $21.2 billion for Q4 2025, versus $21.2 billion for Q3 2025 and $21.2 billion for Q2 2025.